// App-Quantinova.ai

TPS351 : Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

Researchers

Presenter

  • Jennifer J. Knox

Principal Investigators

  • Mairead Geraldine McNamara

  • Lipika Goyal

  • David Cosgrove

  • Christoph Springfeld

  • Katrin Marie Sjoquist

  • Joon Oh Park

  • Helena Verdaguer

  • Chiara Braconi

  • Paul J. Ross

  • Aimery De Gramont

  • Rachna T. Shroff

  • John Raymond Zalcberg

  • Daniel H. Palmer

  • Juan W. Valle

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Massachusetts General Hospital Cancer Center, Boston, MA

  • Sidney Kimmel Comp Cancer Ctr, Baltimore, MD

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • University of Glasgow, Glasgow, United Kingdom

  • Guy's Hospital, London, United Kingdom

  • Franco-British Institute, Levallois-Perret, France

  • University of Arizona Cancer Center, Tucson, AZ

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • University of Liverpool, Liverpool, United Kingdom

  • University of Manchester, The Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

Locations

  • Canada

  • United States

  • Germany

  • Australia

  • Republic of South Korea

  • Spain

  • United Kingdom

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

  • Ampullary carcinoma

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Cisplatin

  • Acelarin

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved